Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors (Q39957477)

15 September 2017

Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors (English)

1 reference

15 September 2017

1 reference

1 reference

5

I Bergman

1 reference

15 September 2017

Y Gao

1

1 reference

15 September 2017

P Whitaker-Dowling

series ordinal

2

1 reference

15 September 2017

J A Griffin

series ordinal

3

1 reference

15 September 2017

M A Barmada

series ordinal

4

1 reference

15 September 2017

25 July 2008

1 reference

15 September 2017

1 reference

15 September 2017

16

1 reference

15 September 2017

1

1 reference

15 September 2017

44-52

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2008.55

15 September 2017

0 references

cites work

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Recombinant measles viruses efficiently entering cells through targeted receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Preferential targeting of vesicular stomatitis virus to breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Recombinant vesicular stomatitis viruses from DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Interleukin-10 and related cytokines and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

Antibody-directed targeting of retroviral vectors via cell surface antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

7 January 2021

Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

7 January 2021

Mechanisms of tumor evasion.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

7 January 2021

Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.55

7 January 2021

Identifiers

DOI

10.1038/CGT.2008.55

1 reference

15 September 2017

1 reference